CRH (CRH) H2 2014 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2014 earnings summary
19 Nov, 2026Executive summary
Earnings and returns grew across all six divisions in 2014; improved margins reflected restructuring, operational and commercial initiatives, and portfolio realignment.
Full-year EBITDA exceeded November guidance after a strong finish in Europe and the U.S.; management expected another year of profit growth in 2015.
Financial highlights
Revenue was just under EUR 19bn, up 5% YoY; EBITDA was EUR 1.64bn, up 11% YoY, and EPS was just under EUR 0.79, up 33%.
Operations generated EUR 902m cash versus EUR 736m in 2013; free operating cash flow was almost EUR 1bn.
Net debt ended 2014 at EUR 2.5bn, EUR 500m below year-end 2013; the dividend was EUR 0.625 per share, with 2014 marking 31 consecutive years of dividends.
Outlook and guidance
2015 was expected to deliver further earnings and returns growth; U.S. backlogs were ~10% higher YoY, while Europe had started positively but faced a tough first-half comparison.
U.S. pricing gains were expected to continue in 2015; European pricing was expected to remain muted as volume recovery was insufficient to support increases.
CapEx was expected to rise closer to depreciation in 2015 as activity improved; working capital could become an outflow, with strong operating cash flow still expected.
After LafargeHolcim, the stated priority was to restore debt metrics to normalized levels by end-2016; the 15%-20% operating-leverage range was not revised.
Latest events from CRH
- Strong organic profit growth and cash generation cut year-end net debt below 3x EBITDA.CRH
H2 2015 - Strong growth and cash generation cut leverage to 1.7x while supporting further growth.CRH
H2 2016 - €3.3bn EBITDA, stronger margins and returns, and major acquisitions positioned for further growth.CRH
H2 2017 - U.S. momentum and cost actions supported 2013 progress as net debt fell EUR 519m.CRH
H2 2012 - H2 momentum improved as portfolio actions and disciplined investment set up a moderate 2014 recovery.CRH
H2 2013 - Sales rose 5% and EBITDA reached €1.66bn as margins proved resilient.CRH
H2 2011 - Cash discipline and cost savings steadied results as markets began to stabilize.CRH
H2 2010 - Q3 EBITDA held near prior year; FY26 guidance is $7.8B–$8.0B amid cost and residential headwinds.CRH
Q3 2026 - Q2 2026 saw strong growth, margin gains, and the Arcosa deal, supporting a positive outlook.CRH
Q2 2026